AVEO AVEO Pharmaceuticals Inc.

0.91
-0.01  -1%
Previous Close 0.92
Open 0.95
Price To Book 91
Market Cap 146,277,475
Shares 160,744,478
Volume 1,187,087
Short Ratio
Av. Daily Volume 2,360,315
Stock charts supplied by TradingView

NewsSee all news

  1. AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

    AVEO Oncology (NASDAQ:AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA® (tivozanib), the Company's once-daily, potent and selective

  2. AVEO Oncology to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at

  3. Thinking about buying stock in AVEO Pharmaceuticals, CAN-FITE Biopharma, Francesca's, AT&T, or Tilray?

    NEW YORK, Sept. 10, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVEO, CANF, FRAN, T, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  4. AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

    - 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm - - Company Plans to Discuss Updated Results with FDA - - AVEO to Host Conference Call Today at 8:00 am Eastern Time - AVEO Oncology

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 2H 2020.
Ficlatuzumab and cetuximab
Head and neck squamous cell carcinoma (HNSCC)
Phase 2 final data presented at ESMO 2019.
Tivozanib + Opdivo
Renal cell cancer (RCC)
Announced September 12, 2016 that its Phase 2 trial has been discontinued
Ficlatuzumab
EGFR-mutated Non-small cell lung cancer (NSCLC)
Phase 3 interim data noted overall survival of 16.4 months vs 19.7 months for sorafenib.
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
Phase 1b poster presented at AACR April 1, 2019. 9/17 CRs.
Ficlatuzumab and cytarabine
Acute myeloid leukemia (AML)
Phase 1/2 trial initiation announced September 30, 2019.
FOTIVDA (Tivozanib) and IMFINZI (Durvalumab)
Hepatocellular carcinoma (HCC)

Latest News

  1. AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

    AVEO Oncology (NASDAQ:AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA® (tivozanib), the Company's once-daily, potent and selective

  2. AVEO Oncology to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at

  3. Thinking about buying stock in AVEO Pharmaceuticals, CAN-FITE Biopharma, Francesca's, AT&T, or Tilray?

    NEW YORK, Sept. 10, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVEO, CANF, FRAN, T, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  4. AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

    - 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm - - Company Plans to Discuss Updated Results with FDA - - AVEO to Host Conference Call Today at 8:00 am Eastern Time - AVEO Oncology